The online version of this article (doi:10.1186/1477-7819-10-80) contains supplementary material, which is available to authorized users.
Qiang Lu, Wei Cao, Lijun Huang, Yi Wan contributed equally to this work.
All of the authors in this manuscript declared that no financial or non-financial interests were related to this study or future application after publication.
QL was responsible for manuscript writing (First Author); WC and LH supervised QL to write this manuscript and gave comments to revise it (co-author); YH and XL were responsible for whole project design (Corresponding Author); YW is in charge of data analysis; TL and QC is in charge of correction of manuscript. All authors read and approved the final manuscript.
Microwave ablation (MWA) has attracted a worldwide attention gradually in treating inoperable pulmonary malignancies. However, in the lung tissues treated with MWA recurrence of tumor may still occur and few data in large patient groups till now were reported about the safety or effectiveness of microwave ablation in treating primary lung cancer and metastatic pulmonary malignancies. The purpose of this study is to evaluate the clinical curative effect (local control, survival data) MWA and its safety as well.
From 1 January 2005 to 1 January 2008, retrospective analyses, 69 patients underwent computed tomography (CT)-guided percutaneous MWA of pulmonary malignancies. All patients were deemed medically inoperable. The correlation of tumor sizes and local progression after ablation was analyzed and the survival rates within 3 years post surgery were compared between non-small-cell lung cancer and pulmonary metastases groups also.
Pneumothorax was the most frequent complication and occurred in 24.64% patients after ablation. Neither needle track implantation was found nor did patient death occur in these patients within 30 days. The 1-, 2-, and 3-year overall survival rates were 66.7%, 44.9% and 24.6%, respectively. The overall survival rates for NSCLC patients in 1 year, 2 years, and 3 years were 75.0%, 54.2%, and 29.2%, respectively. The overall survival rates for pulmonary metastatic tumor patients in 1 year, 2 years, and 3 years were 47.6%, 23.8%, and 14.3%, respectively. The recurrence-free survival rates for NSCLC patients in 1 year, 2 years, and 3 years were 72.9%, 50.0%, and 27.1%, respectively. The mortality rates for pulmonary metastatic tumor patients in 1 year, 2 years, and 3 years were 47.6%, 19.0%, and 14.3%, respectively.
Percutaneous microwave coagulation therapy was one safe and effective method and could be beneficial for the improvement of inoperable pulmonary malignancies treatment effect.
Steel AW, Postgate AJ, Khorsandi S, Nicholls J, Jiao L, Vlavianos P, Habib N, Westaby D: Endoscopically applied radiofrequency ablation appears to be safe in the treatment of malignant biliary obstruction. Gastrointest Endosc. 2010, 73: 149-153. CrossRef
Beland MD, Wasser EJ, Mayo-Smith WW, Dupuy DE: Primary non-small cell lung cancer: review of frequency, location, and time of recurrence after radiofrequency ablation. Radiology. 2009, 254: 301-307.
The National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 2010, , Bethesda, MD, Approved after 1 October 2009
Fernando HC, De Hoyos A, Landreneau RJ, Gilbert S, Gooding WE, Buenaventura PO, Christie NA, Belani C, Luketich JD: Radiofrequency ablation for the treatment of non-small cell lung cancer in marginal surgical candidates. J Thorac Cardiovasc Surg. 2005, 129: 639-644. 10.1016/j.jtcvs.2004.10.019. CrossRefPubMed
Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd GD, Dupuy DE, Gervais DA, Gillams AR, Kane RA, Lee FT, Livraghi T, McGahan J, Phillips DA, Rhim H, Silverman SG, Solbiati L, Vogl TJ, Wood BJ, Vedantham S, Sacks D, Society of Interventional Radiology Technology Assessment Committee and the International Working Group on Image-guided Tumor Ablation: Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2009, 7 (Suppl): S377-S390. CrossRef
de Baere T, Palussiere J, Auperin A, Hakime A, Abdel-Rehim M, Kind M, Dromain C, Ravaud A, Tebboune N, Boige V, Malka D, Lafont C, Ducreux M: Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology. 2006, 240: 587-596. 10.1148/radiol.2402050807. CrossRefPubMed
- CT-guided percutaneous microwave ablation of pulmonary malignancies: Results in 69 cases
- BioMed Central
Neu im Fachgebiet Chirurgie
e.Med Kampagnen-Visual, Mail Icon II